Detecting oligomers in the cerebrospinal fluid is no easy feat. The latest test is among the most sensitive yet, but is it useful?
A new initiative in the U.K. will fund research into potential treatments for dementia and neurodegeneration.
Neurons in mice spit out monomeric tau when electrically stimulated, hinting that neural activity may help drive the spread of pathological forms of tau in the brain.
In Fragile X syndrome, mRNA from the mutant FMR1 gene binds to its own DNA to suppress protein expression. Could the same thing happen in other repeat expansion diseases?
AstraZeneca’s BACE inhibitor AZD3293 moves forward to a Phase 2/3 trial, joining Merck’s MK-8931 as the most advanced current compounds in this class.
The first longitudinal data from DIAN conflict with some cross-sectional findings, revealing a small drop in CSF injury markers after the first appearance of symptoms of disease.
The scientific spotlight often shines on excitatory neurons as the brain’s main Aβ factories. What about other cell types?
Scientists may have discovered another explanation for why DNA repeat sequences cause neurodegenerative diseases: A six-nucleotide expansion in the C9ORF72 gene forms stable structures that interfere with its transcription.
Low levels of 10 phospholipids in blood plasma correlated with future cognitive decline in older adults, hinting at diagnostic potential.
The amyloid imaging agent florbetapir predicts cognitive decline much like its forerunner, PiB.
Research suggests that the kinase Cdk5 limits formation of new memories by keeping a key synaptic receptor away from the cell surface.
Researchers have found protein traces of brain damage in the blood of hockey players who sustained a concussion. Could biomarkers help decide when athletes return to their sport?
A new test claims to detect Aβ oligomers in cerebrospinal fluid by exploiting their tendency to seed aggregation.
Network analysis may explain why people with semantic dementia keep making memories even as their hippocampi degenerate.
Combination therapies may work where single drugs fall short, but testing them in AD may prove challenging.